2022 American Transplant Congress
Association Between De Novo Donor Specific Antibody and Tacrolimus Trough Levels in Long Term Follow Up Renal Transplantation
*Purpose: In this study, we aimed to identify the risk factors contributing to the development of donor-specific anti-HLA antibody (DSA) during long-term follow-up of patients…2022 American Transplant Congress
The Effect of Tacrolimus and Mycophenolic Acid on Torque Teno Virus Loads in Kidney Transplant Recipients
Leiden University Medical Center, Leiden, Netherlands
*Purpose: Measuring immune function in kidney transplant recipients (KTRs) remains challenging given the precarious balance between over- and underimmunosuppression. This is primarily due to high…2022 American Transplant Congress
Detection of Early Graft Injury After Liver Transplantation with Blood-Bile Ratio of Tacrolimus: The TUBE Trial
*Purpose: The aim of the“Tacrolimus in Bile”(TUBE)Trial is the creation of a laboratory parameter for the early detection of hepatic injury after liver transplant.*Methods: TUBE…2022 American Transplant Congress
Effect of Schisandra Sphenanthera Extract on Pharmacokinetics of Tacrolimus in Pediatric Renal Transplant Recipients
*Purpose: Wuzhi tablet (Schisandra sphenanthera extract) is a promising tacrolimus-sparing agent in adult renal transplant recipients, while its effect in pediatric recipients remains unclear. The…2022 American Transplant Congress
Effect of Dual Inhibition of DPP4 and SGLT2 on Tacrolimus-Induced Diabetes Mellitus and Nephrotoxicity in Rat Model
Seoul St.Mary's Hospital, Seoul, Korea, Republic of
*Purpose: Sodium/glucose co-transporter-2 inhibitor (SGLT2i) or dipeptidyl peptidase IV inhibitor (DPP4i) are popular anti-diabetic drugs in type II diabetes mellitus (DM), but their use in…2022 American Transplant Congress
Comparison of Immediate-Release Tacrolimus to Envarsus XR on the Development of Donor Specific Antibodies in Kidney Transplant Recipients
Northwestern Memorial Hospital, Chicago, IL
*Purpose: Major causes of de novo development of donor specific antibodies (DSA) after kidney transplant include medication noncompliance and immunosuppression minimization or elimination that may…2022 American Transplant Congress
Implementing Clinical Decision Support Tools for Immunosuppressant Drug-Drug Interactions to Prevent Graft Failure
1MAPMG, Mc Lean, VA, 2Kaiser Permanente, Silver Spring, MD, 3MAPMG, Rockville, MA
*Purpose: Immunosuppressant drug-drug interactions can result in immunosuppressant toxicity or subtherapeutic levels causing rejection. If not identified and managed appropriately, these interactions may result in…2021 American Transplant Congress
Pharmacokinetic Analysis of Direct Acting Antiviral Use on Weight-Adjusted FK506 Trough/dose Ratios in Obese Kidney Transplant Recipients
*Purpose: Using hepatitis C viremic (HCV) organs in kidney transplant recipients(KTRs) is very important to decrease the number of patients on the waiting list. Direct…2021 American Transplant Congress
De-novo Use Comparison Between Extended-release Once-daily Tacrolimus (Envarsus Xr®) and Immediate-release Twice-daily Tacrolimus (Prograf®) – A Single Center’s Experience
*Purpose: Envarsus XR® is approved for de-novo use post-kidney transplantation at a higher starting dose (0.14mg/kg/day) as compared with Prograf® (0.1 mg/kg/day) despite better bioavailability.…2021 American Transplant Congress
The Impact of De Novo Dose-Adjustment Strategies with Tacrolimus XR (LCP-Tac) in Kidney Transplant Recipients
Medical University of South Carolina, Charleston, SC
*Purpose: LCP-Tac is a once daily formulation of tacrolimus indicated for the prophylaxis of rejection in de novo kidney transplant recipients. It provides less variable…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 14
- Next Page »